mybacs, a start-up company founded in 2018 by Sebastian Wahl and Carl- Philipp von Polheim, which specializes in the development of innovative and highly-dosed synbiotic dietary supplements, is closing another financing round. Among others, the already invested international VC fund Global Founders Capital participated again and also existing angel investors provided further capital. Furthermore, Joyance Partners is the first renowned US investor focusing on life sciences/biotech to join in. The new capital will primarily be used to expand the team and develop a tech platform to further personalize the products.
mybacs aims to revolutionize the healthcare sector around the human microbiome. With their formulation of specifically selected bacteria cultures (probiotics), prebiotics as well as minerals and vitamins, the company focuses on synbiotic dietary supplements, which are tailored to the individual needs and areas of application of its customers.
In 2018, mybacs had a successful market entry with the launch of its travel product Travelbacs – a regionally tailored bacterial composition to prepare the digestion for specific travel regions. After a successful first round of financing in August 2019, the company has since been able to further expand its team and marketing activities. With Dailybacs, the company has furthermore expanded its product portfolio by also providing a synbiotic for daily use, available on a subscription basis, which is specially tailored to the needs of women, men and children.
“We are very pleased about the new round of financing and highly appreciate the trust our investors have placed in us.”Carl-Philipp von Polheim, founder and Co-CEO of mybacs
Our customers’ positive feedback and the accompanying growth since the launch of our Dailybacs once again confirms that there is a great demand for products related to intestinal health and the human microbiome. This is where we want to focus on with the new investment sum by developing further products in order to be able to respond even more specifically to the individual needs of our customers. Accordingly, we will expand our team to include specialists in the fields of technology and data, and will continue to drive forward the personalization of our products with the help of a platform for symptomatic and intelligent data analysis.
mybacs is a Swiss biotechnology and pharmaceutical company with offices in Zug and Munich. The company’s goal is to revolutionize the healthcare market around the human microbiome and thus make a decisive contribution to the health and daily well-being of its customers. Accordingly, mybacs has specialized in the development of innovative and highly-dosed synbiotic dietary supplements. These are tailored to the individual needs and application areas of their customers through their unique formulations of specifically selected bacterial cultures (probiotics), prebiotics as well as minerals and vitamins. All mybacs products are subject to the strictest quality controls and are scientifically tested.
About Global Founders Capital:
Founders drive incredible opportunity in the world, and we are their greatest advocates. That’s because our team has built multi-billion-dollar technology businesses from scratch and has thrived through all the twists and turns of entrepreneurship along with it. Over the past two decades, we have backed over five hundred entrepreneurs worldwide. Facebook, LinkedIn, Slack, Eventbrite, Canva, Away Travel, Zalando, Revolut, Funding Circle, Lazada, Traveloka, Quadpay, Jumia, HelloFresh, and Delivery Hero represent a few of our global successes. Global Founders Capital invests out of twelve offices worldwide.
About Joyance Partners:
Joyance Partners is a venture capital fund focused on emerging science and technology that can help individuals feel happier, healthier, calmer, more confident, and less anxious or subject to pain. Joyance Partners US is directed by Managing Partner Mike Edelhart and Founding Partner William Lohse, who also oversee the Social Starts venture capital partnership funds.
mybacs PR & Communications Team